SURMOUNT-OSA patient-reported outcomes show sleep and quality-of-life gains

A follow-up analysis of the phase 3 SURMOUNT-OSA trials found that tirzepatide improved how people with obstructive sleep apnea (OSA) and obesity said they felt, not just how their sleep looked on lab tests ^[1]. The results, published in a peer-reviewed study, add patient-reported outcomes to earlier findings that tirzepatide lowered the apnea-hypopnea index (AHI), a measure of breathing interruptions during sleep ^[1].

SURMOUNT-OSA included two separate 52-week, placebo-controlled trials of tirzepatide, dosed at 10 mg or 15 mg, in adults with moderate-to-severe OSA and obesity ^[1]. One trial enrolled people who were not using positive airway pressure (PAP) therapy, the standard OSA treatment that uses a machine to keep airways open during sleep. The other trial enrolled PAP users, but researchers had those participants stop PAP before running sleep studies and collecting questionnaire data, so the reported outcomes reflect tirzepatide's effect without PAP support ^[1].

At week 52, people on tirzepatide reported significant improvements compared with placebo on several validated scales ^[1]. These included the PROMIS Sleep-Related Impairment score, which measures how much poor sleep affects daily function, and the PROMIS Sleep Disturbance score, which tracks how disrupted sleep felt ^[1]. Tirzepatide also outperformed placebo on the Functional Outcomes of Sleep Questionnaire Activity-Level score, the EQ-5D-5L general health measure, and most domains of the SF-36v2, a broad quality-of-life survey ^[1]. In the trial of participants not using PAP, tirzepatide also produced significant improvement on the Epworth Sleepiness Scale, which measures how likely someone is to doze off during everyday activities ^[1]. People taking tirzepatide also reported greater improvement on global impression scales asking how their OSA symptoms had changed overall ^[1].

Why it matters for patients

OSA is already known to raise cardiovascular risk and disrupt daily life through poor sleep and daytime fatigue ^[1]. Most prior tirzepatide research on OSA focused on the AHI, a number that tells clinicians how often breathing stops or slows during sleep but doesn't capture how a person feels day to day. This analysis matters because it shows tirzepatide was also linked to reported gains in sleep quality, energy, and general well-being, which are the things patients with OSA often say bother them most ^[1].

For people with obesity and OSA who are not using PAP, the sleepiness improvement is notable because excessive daytime sleepiness is one of the more disruptive symptoms of the condition, affecting concentration, mood, and safety around tasks like driving ^[1]. The quality-of-life gains, measured across sleep-specific and general health scales, suggest the drug's benefits may extend beyond the numbers seen on a sleep study printout ^[1].

It is not yet known from this analysis how these patient-reported improvements compare in size or durability to what PAP therapy alone provides, since PAP was withdrawn before testing in one of the two trials ^[1]. It is also not stated in this study how the findings apply to people with mild OSA, since both trials enrolled only those with moderate-to-severe disease ^[1].

What happens next

The study, funded by Eli Lilly and Company, maker of tirzepatide, was published following the original SURMOUNT-OSA results, which have already been used to support marketing claims for the drug in this population ^[1]. The paper does not specify additional planned trials or regulatory steps tied to these patient-reported findings ^[1]. Readers considering treatment options for OSA and obesity may want to discuss these results with a healthcare provider familiar with their full medical history, since the source material does not offer individualized treatment guidance.